Clicky

TG Therapeutics, Inc.(TGTX)

Description: TG Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of innovative and medically important pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two advanced therapies targeting hematological malignancies. The TGTX-1101 (ublituximab) is a novel, third generation monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes, which is in clinical development for patients with relapsed and refractory non-Hodgkin's lymphoma. The TGR-1202 is an orally available PI3K delta inhibitor believed to be important in the proliferation and survival of B-lymphocytes. TG Therapeutics, Inc. is headquartered in New York, New York.


Keywords: Cancer Biopharmaceutical Pharmaceutical Products Treatment Of Cancer Monoclonal Antibodies Clinical Development Lymphoma Monoclonal Antibody Hematological Malignancies Antibody Drug Conjugate Lymphocytes Camidanlumab Tesirine Cd20 Hodgkin's Lymphoma

Home Page: www.tgtherapeutics.com

TGTX Technical Analysis

2 Gansevoort Street
New York, NY 10014
United States
Phone: 212 554 4484


Officers

Name Title
Mr. Michael S. Weiss Esq. Chairman, CEO & Pres
Mr. Sean A. Power CPA, CPA CFO, Corp. Sec. & Treasurer
Jenna Bosco Sr. VP of Corp. Communications
Mr. Adam Waldman Chief Commercialization Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 10.8774
Price-to-Sales TTM: 249.2734
IPO Date: 1995-12-14
Fiscal Year End: December
Full Time Employees: 186
Back to stocks